Return to Research Home
Evidence Grading

How We Grade Evidence

Not every peptide claim deserves the same level of confidence. Peptide Pressure separates strong evidence from early, preclinical, limited, or mixed evidence.

01

Evidence Labels

Evidence
Strong

Supported by substantial human clinical data, FDA-reviewed drug evidence for specific indications, or multiple well-designed human studies.

Evidence
Moderate

Supported by meaningful human data, but not enough to justify broad claims outside the studied context.

Evidence
Early

Some human or translational evidence exists, but the research is still developing.

Evidence
Preclinical

Mostly supported by animal, cell, or mechanistic research.

Evidence
Limited

Evidence is thin, inconsistent, old, poorly replicated, or not strong enough for confident claims.

Evidence
Mixed

Findings are inconsistent or depend heavily on context, formulation, route, population, or study design.

02

Human Evidence vs Preclinical Evidence

Human evidence and preclinical evidence are not the same. Animal and cell studies can explain mechanisms, but they do not automatically prove that a compound is safe or effective in humans.

03

Regulatory Status Matters

A compound may be interesting in research without being FDA-approved for general human use. Peptide Pressure separates research interest from approved medical use.

04

Marketing Claims Are Not Evidence

Supplier claims, social media claims, before-and-after stories, and anecdotal reports are not the same as clinical evidence.

Disclaimer

Evidence grading is educational only. It does not provide medical advice, dosing instructions, treatment recommendations, or personalized healthcare guidance.

Find Your Research Path